Literature DB >> 10024935

Diabetic peripheral neuropathy and quality of life.

S J Benbow1, M E Wallymahmed, I A MacFarlane.   

Abstract

The quality of life (QOL) of 79 people with type 1 and type 2 diabetes and 37 non-diabetic controls was assessed using the Nottingham Health Profile (NHP). The NHP consists of six domains assessing energy, sleep, pain, physical mobility, emotional reactions and social isolation. Symptomatic diabetic neuropathy was present in 41 of the patients. The neuropathy patients had significantly higher scores (impaired QOL) in 5/6 NHP domains than either the other diabetic patients (p < 0.01) or the non-diabetic (p < 0.001) controls. These were: emotional reaction, energy, pain, physical mobility and sleep. The diabetic patients without neuropathy also had significantly impaired QOL for 4/6 NHP domains compared with the non-diabetic control group (p < 0.05) (energy, pain, physical mobility and sleep). This quantification of the detrimental effect on QOL of diabetes, and in particular of chronic symptomatic peripheral diabetic neuropathy, emphasizes the need for further research into effective management of these patients.

Entities:  

Mesh:

Year:  1998        PMID: 10024935     DOI: 10.1093/qjmed/91.11.733

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  58 in total

1.  The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy.

Authors:  C J Currie; C D Poole; A Woehl; C Ll Morgan; S Cawley; M D Rousculp; M T Covington; J R Peters
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

2.  Treating painful diabetic polyneuropathy.

Authors:  Edward B Jude; Nicolaas Schaper
Journal:  BMJ       Date:  2007-07-14

3.  Validation of the Malay version of Diabetes Quality of Life (DQOL) Questionnaire for Adult Population with Type 2 Diabetes Mellitus.

Authors:  Mohamad Adam Bujang; Mastura Ismail; Nur Khairul Bariyyah Mohd Hatta; Siti Haslina Othman; Nurakmal Baharum; Siti Sara Mat Lazim
Journal:  Malays J Med Sci       Date:  2017-08-18

4.  Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure.

Authors:  Meryl Brod; Steven I Blum; Donald M Bushnell; Abhilasha Ramasamy
Journal:  Qual Life Res       Date:  2015-06-12       Impact factor: 4.147

5.  Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.

Authors:  Amanda Boyd; Carolina Casselini; Etta Vinik; Aaron Vinik
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

Review 6.  Measures of health-related quality of life in diabetes-related foot disease: a systematic review.

Authors:  F R A Hogg; G Peach; P Price; M M Thompson; R J Hinchliffe
Journal:  Diabetologia       Date:  2012-01-14       Impact factor: 10.122

Review 7.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

8.  German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity.

Authors:  Etta J Vinik; James F Paulson; Stephanie L Ford-Molvik; Aaron I Vinik
Journal:  J Diabetes Sci Technol       Date:  2008-11

9.  Opioid utilization patterns among medicare patients with diabetic peripheral neuropathy.

Authors:  Jacqueline Pesa; Roxanne Meyer; Tiffany P Quock; Stacy K Rattana; Samir H Mody
Journal:  Am Health Drug Benefits       Date:  2013-05

10.  Evaluation of the reliability and validity of the Medical Outcomes Study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial.

Authors:  Muriel Viala-Danten; Susan Martin; Isabelle Guillemin; Ron D Hays
Journal:  Health Qual Life Outcomes       Date:  2008-12-17       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.